<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00769041</url>
  </required_header>
  <id_info>
    <org_study_id>TA-140</org_study_id>
    <nct_id>NCT00769041</nct_id>
  </id_info>
  <brief_title>A Thorough EKG Safety Study of TA-1790 (Avanafil)</brief_title>
  <official_title>A Blinded, Randomized Crossover Trial to Define the ECG Effects of TA-1790 (Avanafil) Using a Single Clinical and a Supratherapeutic Dose Compared to Placebo and Moxifloxacin in Healthy Men: A Thorough ECG Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VIVUS, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Covance</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>VIVUS, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess whether treatment with a therapeutic (100 mg) or supratherapeutic
      (800 mg) dose of avanafil has the potential to cause QT/QTc prolongation in healthy
      volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time-matched change from baseline in QTcI that provides optimization of QT correction of heart rate as compared to fixed exponent approaches such as QTcB or QTcF.</measure>
    <time_frame>24 Hours</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>moxifloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>avanafil therapeutic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>avanafil 100mg - therapeutic dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>avanafil supratherapeutic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>avanafil 800mg - supratherapeutic dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>moxifloxacin</intervention_name>
    <description>400mg</description>
    <arm_group_label>moxifloxacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>avanafil</intervention_name>
    <description>100mg single dose</description>
    <arm_group_label>avanafil therapeutic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>avanafil</intervention_name>
    <description>800mg single dose</description>
    <arm_group_label>avanafil supratherapeutic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sugar pill</intervention_name>
    <description>single dose</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male;

          2. Between 18 and 45 years of age, inclusive;

          3. Have a BMI ranging between 19 and 28 kg/m2, inclusive;

          4. Have no clinically significant abnormal findings on the physical examination, ECG,
             blood pressure, HR, medical history, or clinical laboratory results during Screening;

          5. Be willing and able to comply with all trial requirements; and

          6. Have given written informed consent.

        Exclusion Criteria:

          1. Subjects who have participated in another clinical trial of an within the last 30 days
             or are currently participating in another trial of an investigational drug.

          2. Subjects who have participated in a previous clinical trial with avanafil.

          3. Subjects who have a known allergy or hypersensitivity to avanafil, sildenafil
             (ViagraÂ®), vardenafil (LevitraÂ®), tadalafil (CialisÂ®) or any of the components of
             these drug products; moxifloxacin or its components; or to any quinolone antibiotic.

          4. Subjects who have experienced dose-limiting adverse effects during therapy with a PDE5

          5. Subjects who have any condition possibly affecting drug absorption

          6. Subjects who have evidence or history of clinically significant allergic (except for
             untreated, asymptomatic, seasonal allergies at time of dosing), hematological,
             endocrine,pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or
             neurological disease. Exceptions to these criteria (eg, stable, mild joint disease)
             may be made following discussions with the Medical Monitor.

          7. Subjects with a medical history of or who have a positive serology test for human
             immunodeficiency virus (HIV), hepatitis B virus surface antigen (HBsAg), or hepatitis
             C virus (HCV).

          8. Subjects who have a history of drug or alcohol abuse or dependence within 18 months
             prior to Screening.

          9. Subjects who have donated blood or blood components within the 4 weeks prior to Period
             1 Check-in.

         10. Subjects with laboratory values outside of the normal range for the local laboratory.

         11. Subjects who have a sustained supine SBP &gt;140 mmHg or &lt;100 mm Hg or a DBP &gt;95 mmHg at
             Screening or baseline.

         12. Subjects who have a resting HR of &lt;45 bpm or &gt;100 bpm.

         13. Subjects who have an abnormal Screening ECG indicating a second- or third-degree
             atrioventricular (AV) block, or 1 or more of the following: QRS interval &gt;110 msec,
             QTc interval &gt;450 msec, PR interval &gt;240 msec, or any rhythm other than sinus rhythm,
             which is interpreted by the Investigator to be clinically significant.

         14. Subjects who use or have used tobacco-containing products within the 6 months prior to
             Period 1 Check-in and throughout the study.

         15. Subjects who have consumed alcohol-, caffeine-, or xanthine-containing products within
             72 hours prior to Period 1 Check-in and throughout the study.

         16. Subjects who test positive for drug(s) of abuse, alcohol, or cotinine at Screening or
             Check-in for any period.

         17. Subjects who have concomitant medication usage of any nitrate, trazadone,
             ketoconozole, erythromycin, cimetidine, androgen replacement therapy and/or use of
             other prescription or over-the-counter drugs that are known to interfere with
             metabolism by CYP3A4.

         18. Subjects who have used any drug that may prolong the QT/QTc interval within 30 days.

         19. Subjects who have used a prescription drug or over-the-counter or herbal medication
             within 14 days

         20. Subjects who are involved in the planning and/or conduct of the study.

         21. Subjects who, for any reason, are deemed by the Investigator to be inappropriate for
             this study, including subjects who are unable to communicate or to cooperate with the
             Investigator.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chuck Bowden, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>VIVUS, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Phase 1 Clinical Unit</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2008</study_first_submitted>
  <study_first_submitted_qc>October 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2008</study_first_posted>
  <last_update_submitted>January 5, 2011</last_update_submitted>
  <last_update_submitted_qc>January 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2011</last_update_posted>
  <responsible_party>
    <name_title>Wesley Day, VP Clinical</name_title>
    <organization>VIvus, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

